Tiziana Life Sciences Ltd
NASDAQ:TLSA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Chongqing Sifang New Material Co Ltd
SSE:605122
|
CN |
|
A
|
Arise AB
STO:ARISE
|
SE |
|
Titan International Inc
NYSE:TWI
|
US |
|
B
|
Blade Air Mobility Inc
NASDAQ:BLDE
|
US |
Tiziana Life Sciences Ltd
Total Receivables
Tiziana Life Sciences Ltd
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Tiziana Life Sciences Ltd
NASDAQ:TLSA
|
Total Receivables
$4.9m
|
CAGR 3-Years
0%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Total Receivables
$35.6m
|
CAGR 3-Years
19%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Total Receivables
£75.8m
|
CAGR 3-Years
17%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Total Receivables
$15.4m
|
CAGR 3-Years
0%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Total Receivables
£124.5m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
5%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Total Receivables
£65.2m
|
CAGR 3-Years
4%
|
CAGR 5-Years
5%
|
CAGR 10-Years
18%
|
|
Tiziana Life Sciences Ltd
Glance View
Tiziana Life Sciences Ltd. engages in the research and development of biotechnological and pharmaceutical products. The firm is focused on the discovery and development of molecules and related diagnostics to treat unmet medical needs in oncology and immunology. Its lead product candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501), and Milciclib TZLS-201. Foralumab (TZLS-401) is a fully human engineered anti-human cluster of differentiation 3 (CD3) monoclonal antibody (mAb). Foralumab is developed for the treatment of neurodegenerative diseases such as progressive Multiple Sclerosis (MS), and Crohn’s disease. The Anti IL-6R mAb (TZLS-501) is a fully human engineered mAb targeting the interleukin-6 receptor (IL-6R). Anti-IL-6R antibody can be used in combination with Foralumab or other anti-inflammatory and anti-infective agents as therapy for COVID-19 and oncology indications. The firm has developed Milciclib TZLS-201 for the treatment of hepatocellular carcinoma (HCC).
See Also
What is Tiziana Life Sciences Ltd's Total Receivables?
Total Receivables
4.9m
USD
Based on the financial report for Jun 30, 2025, Tiziana Life Sciences Ltd's Total Receivables amounts to 4.9m USD.
What is Tiziana Life Sciences Ltd's Total Receivables growth rate?
Total Receivables CAGR 5Y
13%
Over the last year, the Total Receivables growth was -21%.
